{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:22:29Z","timestamp":1793110949267,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.kint.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T13:14:06Z","timestamp":1738329246000},"page":"640-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Treatment of patients with IgA nephropathy: a call for a new paradigm"],"prefix":"10.1016","volume":"107","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-6876","authenticated-orcid":false,"given":"Amelie","family":"Bernier-Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-7229","authenticated-orcid":false,"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.01.014_bib1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2025.01.014_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-Term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib3","article-title":"Albuminuria predicts kidney events in IgA nephropathy","author":"Faucon","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib4","article-title":"Long-term outcomes of patients with IgA nephropathy in the German CKD cohort","volume":"17","author":"Stamellou","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2025.01.014_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib6","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.ekir.2023.09.020","article-title":"Evaluating progression risk in patients with immunoglobulin A nephropathy","volume":"8","author":"Cattran","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.01.014_bib7","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2025.01.014_bib8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.34067\/KID.0000000000000195","article-title":"Systematic review of the Oxford Classification of IgA Nephropathy: reproducibility and prognostic value","volume":"4","author":"Howie","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2025.01.014_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib11","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/ndt\/gfy337","article-title":"Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort","volume":"34","author":"Bellur","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41467-023-36173-0","article-title":"Next-Generation Morphometry for pathomics-data mining in histopathology","volume":"14","author":"Holscher","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.01.014_bib13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.kint.2025.01.014_bib14","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.kint.2020.10.033","article-title":"Updating the International IgA Nephropathy Prediction Tool for use in children","volume":"99","author":"Barbour","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.01.014_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.ajkd.2019.07.019","article-title":"Change in albuminuria and estimated GFR as end points for clinical trials in early stages of CKD: a perspective from European regulators","volume":"75","author":"Holtkamp","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.01.014_bib18","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib19","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A\u00a0meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2025.01.014_bib20","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib21","first-page":"320","article-title":"Glucocorticoids and control of glomerular filtration rate","volume":"10","author":"Baylis","year":"1990","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib22","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.01.014_bib24","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/sim.8282","article-title":"Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease","volume":"38","author":"Vonesh","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2025.01.014_bib25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.01.014_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A\u00a0phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2025.01.014_bib27","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1681\/ASN.2017010108","article-title":"Remission of hematuria improves renal survival in IgA nephropathy","volume":"28","author":"Sevillano","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2025.01.014_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.amjmed.2012.06.028","article-title":"Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor","volume":"126","author":"Li","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2025.01.014_bib30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.01.014_bib31","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib32","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ekir.2021.02.018","article-title":"Supportive management of IgA nephropathy with renin-angiotensin blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) study","volume":"6","author":"Bagchi","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.01.014_bib33","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2025.01.014_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kint.2025.01.014_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib36","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2025.01.014_bib37","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A\u00a0phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib38","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20244pzx4j11","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","author":"Barratt","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib39","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib41","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2024erjkjke1","article-title":"The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial","author":"Heerspink","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib42","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial","author":"Lafayette","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib43","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.01.014_bib44","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.ekir.2023.07.023","article-title":"Targeting the endothelin A receptor in IgA nephropathy","volume":"8","author":"Kohan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.01.014_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.33549\/physiolres.933670","article-title":"Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis","volume":"67","author":"Tycova","year":"2018","journal-title":"Physiol Res"},{"key":"10.1016\/j.kint.2025.01.014_bib46","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease","volume":"310","author":"Komers","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.kint.2025.01.014_bib47","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.01.014_bib48","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2025.01.014_bib49","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.01.014_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2025.01.014_bib51","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2025.01.014_bib52","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1097\/MS9.0000000000001180","article-title":"Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis","volume":"85","author":"Yasmin","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.kint.2025.01.014_bib53","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2024t1x172tm","article-title":"Concomitant sparsentan and SGLT2 inhibitors in adults with IgA nephropathy in the ongoing phase 2 SPARTACUS trial (abstract)","volume":"35","author":"Ayoub","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111254","article-title":"Renin-angiotensin system and inflammation update","volume":"529","author":"Cantero-Navarro","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.kint.2025.01.014_bib55","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A\u00a0randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib56","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/ckj\/sfad041","article-title":"Future landscape for the management of membranous nephropathy","volume":"16","author":"Caravaca-Fontan","year":"2023","journal-title":"Clin Kidney J"},{"issue":"suppl 1","key":"10.1016\/j.kint.2025.01.014_bib57","article-title":"Felzartamab (anti-CD38) in patients with IgA nephropathy\u2014interim results from the IGNAZ study (abstract)","volume":"39","author":"Floege","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib58","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MOG.0000000000000789","article-title":"Role of gut-kidney axis in renal diseases and IgA nephropathy","volume":"37","author":"Monteiro","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.kint.2025.01.014_bib60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib61","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/S0140-6736(17)32138-4","article-title":"Targeted-release budesonide therapy for IgA nephropathy\u2014authors' reply","volume":"390","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.01.014_bib62","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.01.014_bib64","first-page":"6927","article-title":"A\u00a0PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin a nephropathy: a review of the evidence","volume":"12","author":"Mathur","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2025.01.014_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2025.01.014_bib66","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The role of APRIL and BAFF in lymphocyte activation","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr Opin Immunol"},{"issue":"suppl 1","key":"10.1016\/j.kint.2025.01.014_bib67","article-title":"#812 Phase 2b ORIGIN study open label extension with atacicept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis","volume":"39","author":"Lafayette","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 1","key":"10.1016\/j.kint.2025.01.014_bib68","article-title":"#1342 Updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in autoantibody-associated glomerulonephritis","volume":"39","author":"Madan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib69","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.01.014_bib70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.01.014_bib71","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.01.014_bib72","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib73","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib74","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/ndt\/gfn161","article-title":"Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy","volume":"23","author":"Lv","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib75","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib76","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib77","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.01.014_bib78","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib79","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib80","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.01.014_bib81","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib82","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac150","article-title":"The human glucocorticoid receptor beta: from molecular mechanisms to clinical implications","volume":"163","author":"Nicolaides","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2025.01.014_bib83","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.01.014_bib85","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2025.01.014_bib86","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/ndt\/gfac221","article-title":"TESTING the effects of corticosteroids in patients with IgA nephropathy","volume":"37","author":"Seikrit","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib87","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12882-024-03481-6","article-title":"Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study","volume":"25","author":"Riveda","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib89","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030422","article-title":"Immunosuppressive therapy versus supportive care in IgA nephropathy patients with stage 3 and 4 chronic kidney disease","volume":"101","author":"Stefan","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2025.01.014_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268421","article-title":"The epidemiology and evolution of IgA nephropathy over two decades: a single centre experience","volume":"17","author":"Storrar","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.01.014_bib91","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: the lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib92","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1093\/ndt\/gfad140","article-title":"The complement system in IgAN: mechanistic context for therapeutic opportunities","volume":"38","author":"Duval","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib93","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2025.01.014_bib94","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2023.10.012","article-title":"A\u00a0new alternative: inhibiting complement activation in patients with IgA nephropathy","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.01.014_bib96","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib97","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2025.01.014_bib98","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1093\/ndt\/gfm393","article-title":"Treatment targets in renal fibrosis","volume":"22","author":"Boor","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.01.014_bib99","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/kisup.2014.12","article-title":"Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis","volume":"4","author":"Ostendorf","year":"2014","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2025.01.014_bib101","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41581-021-00440-4","article-title":"Non-invasive molecular imaging of kidney diseases","volume":"17","author":"Klinkhammer","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib102","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2025.01.014_bib104","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1016\/j.kint.2025.09.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825000766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825000766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:04:42Z","timestamp":1769173482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825000766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0085253825000766"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.01.014","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of patients with IgA nephropathy: a call for a new paradigm","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}